Abstract
During 4 weeks of treatment with clorgyline, a selective MAO-A inhibitor, platelet monoamine oxidase (MAO) activity was unchanged. During a similar 4-week crossover treatment period with pargyline, a selective MAO-B inhibitor, platelet MAO activity was essentially completely inhibited in the same individuals. The differential effects of the two drugs on platelet MAO, which consists exclusively of the MAO-B form, suggests that the in vitro selectivity of clorgyline, and possibly of pargyline, on MAO-A and MAO-B may be maintained in vivo during long-term administration in man. Reductions in blood pressure, heart rate, and plasma amine oxidase activity were generally similar in magnitude during treatment with both drugs, however, suggesting that either these effects are nonspecific consequences of both MAO-A and MAO-B inhibition, or that pargyline also inhibited MAO-A activity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abrams, W. B.: MAO inhibitors: their pharmacology and place in hypertension. In: Hypertension, mechanisms and management, G. Onesti, H. Kim, and J. Moyer (eds.), pp. 311–321, New York: Grune and Stratton 1973
Bakhle, Y. S., Youdim, M. B. H.: Metabolism of phenylethylamine in rat isolated perfused lung: evidence for monoamine oxidase ‘Type B’ in lung. Br. J. Pharmacol. 56, 125–127 (1976)
Christmas, A. J., Coulson, C. J., Maxwell, D. R., Riddell, D.: A comparison of the pharmacological and biochemical properties of substrate-selective monoamine oxidase inhibitors. Br. J. Pharmacol. 45, 490–503 (1972)
Donnelly, C. H., Murphy, D. L.: Substrate and inhibitor-related characteristics of human platelet monoamine oxidase. Biochem. Pharmacol. 26, 853–858 (1977)
Donnelly, C. H., Richelson, E., Murphy, D. L.: Properties of monoamine oxidase in mouse neuroblastoma N1E-115 cells. Biochem. Pharmacol. 25, 1639–1643 (1976)
Dunlop, E.: Antidepressant effects of MAO inhibitors. Ann. N.Y. Acad. Sci. 107, 1107–1116 (1963)
Edwards, D. J., Venetti, C.: Octopamine: a substrate for types A and B monoamine oxidase. Soc. Neuroscience Proc., p. 313. 1977
Fuentes, J. A., Neff, N. H.: Selective monoamine oxidase inhibitor drugs as aids in evaluating the role of type A and B enzymes. Neuropharmacology 14, 819–825 (1975)
Goridis, C., Neff, N. H.: Monoamine oxidase in sympathetic nerves: a transmitter specific enzyme type. Br. J. Pharmacol. 43, 814–818 (1971)
Herd, J. A.: A new antidepressant — M and B 9302. A pilot study and a double-blind controlled trial. Clin. Trials 6, 219–225 (1969)
Houslay, M. D., Tipton, K. F., Youdim, M. B. H.: Multiple forms of monoamine oxidase, fact and artifact. Life Sci. 19, 467–478 (1976)
Jarrott, B.: Occurrence and properties of monoamine oxidase in adrenergic neurons. J. Neurochem. 18, 7–16 (1971)
Johnston, J. P.: Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem. Pharmacol. 17, 1285–1297 (1968)
Kopin, I. J., Fischer, J. E., Musacchio, J., Horst, W. D.: Evidence for a false neurochemical transmitter as a mechanism for the hypotensive effect of monoamine oxidase inhibitors. Biochemistry 52, 716–721 (1964)
Lipper, S., Murphy, D. L., Slater, S., Buchsbaum, M. S.: Comparative behavioral effects of clorgyline and pargyline in man: A preliminary evaluation. Psychopharmacology 62, 123–128 (1979)
Murphy, D. L.: Substrate-selective monoamine oxidases: inhibitor, tissue, species and functional differences. Biochem. Pharmacol. 27, 1889–1893 (1978)
Murphy, D. L., Cahan, D. H., Molinoff, P. B.: Occurrence, transport and storage of octopamine in human blood platelets. Clin. Pharmacol. Ther. 18, 587–593 (1975)
Murphy, D. L., Donnelly, C. H.: Monoamine oxidase in man: enzyme characteristics in platelets, plasma and other human tissues. In: Neuropsychopharmacology of monoamines and their regulatory enzymes, E. Usdin (ed.), pp. 71–85. New York: Raven 1974
Murphy, D. L., Wright, C., Buchsbaum, M., Nichols, A., Costa, J. L., Wyatt, R. J.: Platelet and plasma amine oxidase activity in 680 normals: sex and age differences and stability over time. Biochem. Med. 16, 254–265 (1976)
Neff, N. H., Yang, H.-Y. T.: Another look at the monoamine oxidases and the monoamine oxidase inhibitor drugs. Life Sci. 14, 2061–2074 (1974)
Rando, R. R., de Mairena, J.: Propargylamine-induced irreversible inhibition of non-flavin-linked amine oxidases. Biochem. Pharmacol. 23, 463–466 (1974)
Roth, J. A., Gillis, C. N.: Inhibition of lung, liver and brain monoamine oxidase by imipramine and desipramine. Biochem. Pharmacol. 23, 1138–1140 (1974)
Saunders, J. C.: Treatment of hospitalized depressed and schizophrenic patients with monoamine oxidase inhibitors: including reflections on pargyline. Ann. N.Y. Acad. Sci. 107, 1081–1089 (1963)
Squires, R. F.: Multiple forms of monoamine oxidase in intact mitochondria as characterized by selective inyibition and thermal stability: a comparison of eight mammalian species. Adv. Biochem. Pharmacol. 5, 355–370 (1972)
Wheatley, D.: Comparative trial of a new mono-amine oxidase inhibitor in depression. Br. J. Psychiatry 117, 573–574 (1970)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Murphy, D.L., Lipper, S., Slater, S. et al. Selectivity of clorgyline and pargyline as inhibitors of monoamine oxidases A and B in vivo in man. Psychopharmacology 62, 129–132 (1979). https://doi.org/10.1007/BF00427125
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00427125